http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EC-SP14007965-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae10212794160b34478f0d05b6ab6fd7
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2826
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
filingDate 2014-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_930b9a891c0d033244cf0ccbb847b85e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_106dce5a6381f89fa05f5feaf550df1a
publicationDate 2015-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EC-SP14007965-A
titleOfInvention FORMULATIONS OF (+) - 2- [1- (3-ETOXY-4-METOXY-PHENYL) -2-METANSULPHONYL-ETHYL] -4-ACETYL AMINOISOINDOLIN-1, 3-DIONA
abstract Pharmaceutical compositions and simple unit dosage forms of (+) - 2- [1- (3-ethoxy-4-methoxy-phenyl) -2-methanesulfonyl-ethyl] -4-acetylaminoisoindoline-1,3-dione, or a A prodrug stereoisomer, pharmaceutically acceptable salt, solvate, hydrate or clathrate thereof, is provided herein. Methods for treating, managing, or preventing various diseases or disorders are also provided. The compound is known as Apremilast and has the following structural formula: (I)
priorityDate 2011-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11561674
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419496369
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420400772
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10151715

Total number of triples: 34.